Partnering

At Zogenix, our core strategy is to commercialize and develop differentiated CNS and pain therapeutics that can address significant unmet medical needs and overcome limitations of existing products.  A key element of this strategy is to expand our product pipeline in CNS disorders and/or pain by out-licensing our proprietary DosePro needle-free drug delivery technology and securing rights to complementary products and product candidates that address CNS disorders and/or pain.

Specifically, we are seeking opportunities to out-license the DosePro needle-free drug delivery technology to partners seeking to enhance, differentiate or extend the life-cycle of their injectable products.

We will also consider in-licensing or acquisition opportunities with a focus on product candidates that utilize novel technologies to improve the profile of existing compounds for CNS disorders and/or pain.

For further information about partnering opportunities, please contact us.